Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (244)	3/28/1998 1:19:00 AM
From: Rob	Read Replies (1) \| Respond to of 305

Having followed this company through three CEO's and shared everyone's pain for a number of years, it's time to put this company out of our misery. For those looking for something interesting to fill the void, I suggest taking a look at Inflazyme Pharm. ( OTC:IZYPF) (VSE:IZP) at ~0.70 cents. There is an excellent thread on the Silicon Investor and their web site ( www.inflazyme.com) is informative. This company is very close to a "strategic inflection point". Their product is a new class of steroid-like compounds for inflammation based on inhibition of nuclear factor kappa beta. Goldman Sachs is involved in this company as well as Rothchild. It's worth a look, the science is solid.